

# Luana Lionetto

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4920063/publications.pdf>

Version: 2024-02-01

81  
papers

2,217  
citations

218381

26  
h-index

253896

43  
g-index

82  
all docs

82  
docs citations

82  
times ranked

3500  
citing authors

#	ARTICLE	IF	CITATIONS
1	Polyamines serum levels in episodic and chronic migraine. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 249-254.	1.4	4
2	Increased kynurenine-to-tryptophan ratio in the serum of patients infected with SARS-CoV2: An observational cohort study. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2021, 1867, 166042.	1.8	61
3	Intestinal Permeability and Circulating CD161+CCR6+CD8+T Cells in Patients With Relapsing/Remitting Multiple Sclerosis Treated With Dimethylfumarate. <i>Frontiers in Neurology</i> , 2021, 12, 683398.	1.1	5
4	Profiling lasmiditan as a treatment option for migraine. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 147-153.	0.9	18
5	The Trace Kynurenine, Cinnabaric Acid, Displays Potent Antipsychotic-Like Activity in Mice and Its Levels Are Reduced in the Prefrontal Cortex of Individuals Affected by Schizophrenia. <i>Schizophrenia Bulletin</i> , 2020, 46, 1471-1481.	2.3	20
6	5-Fluorouracil degradation rate as a predictive biomarker of toxicity in breast cancer patients treated with capecitabine. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 1836-1842.	0.5	8
7	Tryptophan and Kynurenine Metabolites: Are They Related to Depression?. <i>Neuropsychobiology</i> , 2019, 77, 23-28.	0.9	29
8	Sudden Death Associated with Complex Treatment of Acute Mania: Case Report and Toxicological Findings. <i>Current Psychopharmacology</i> , 2019, 8, 238-243.	0.1	2
9	Fremanezumab for the preventive treatment of migraine in adults. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 741-748.	1.3	13
10	Urinary and exhaled biomarkers of exercise-induced bronchoconstriction in atopic asthmatic children. <i>Pediatric Pulmonology</i> , 2019, 54, 1447-1456.	1.0	5
11	Serum xanthurenic acid levels: Reduced in subjects at ultra high risk for psychosis. <i>Schizophrenia Research</i> , 2019, 208, 465-466.	1.1	9
12	DHA Oral Supplementation Modulates Serum Epoxydocosapentaenoic Acid (EDP) Levels in Breast Cancer Patients. <i>Oxidative Medicine and Cellular Longevity</i> , 2019, 2019, 1-7.	1.9	2
13	How do you choose the appropriate migraine pharmacotherapy for an elderly person?. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1-3.	0.9	13
14	Lacosamide in bipolar disorder: A 30-day comparison to a retrospective control group treated with other antiepileptics. <i>Psychiatry and Clinical Neurosciences</i> , 2018, 72, 864-875.	1.0	7
15	Pharmacogenetic considerations for migraine therapies. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 1-7.	1.5	12
16	Maternal exposure to endocrine disruptors and placental transmission: a pilot study. <i>Gynecological Endocrinology</i> , 2018, 34, 1001-1004.	0.7	21
17	Cinnabaric acid and xanthurenic acid: Two kynurenine metabolites that interact with metabotropic glutamate receptors. <i>Neuropharmacology</i> , 2017, 112, 365-372.	2.0	63
18	Altered intestinal permeability in patients with relapsing/remitting multiple sclerosis: A pilot study. <i>Multiple Sclerosis Journal</i> , 2017, 23, 442-446.	1.4	107

#	ARTICLE	IF	CITATIONS
19	Lasmiditan for the treatment of migraine. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 227-234.	1.9	36
20	Changes in serum levels of kynurenine metabolites in paediatric patients affected by ADHD. <i>European Child and Adolescent Psychiatry</i> , 2017, 26, 1433-1441.	2.8	25
21	5-Fluorouracil degradation rate could predict toxicity in stages II&III colorectal cancer patients undergoing adjuvant FOLFOX. <i>Anti-Cancer Drugs</i> , 2017, 28, 322-326.	0.7	10
22	A nomogram to predict 5-fluorouracil toxicity. <i>Anti-Cancer Drugs</i> , 2017, 28, 551-556.	0.7	10
23	A Critical Evaluation on MOH Current Treatments. <i>Current Treatment Options in Neurology</i> , 2017, 19, 32.	0.7	17
24	Evaluation of 5-fluorouracil degradation rate and Pharmacogenetic profiling to predict toxicity following adjuvant Capecitabine. <i>European Journal of Clinical Pharmacology</i> , 2017, 73, 157-164.	0.8	12
25	Pre-treatment assay of 5-fluorouracil degradation rate (5-FUDR) to improve prediction of 5-fluorouracil toxicity in gastro-esophageal cancer. <i>Oncotarget</i> , 2017, 8, 14050-14057.	0.8	6
26	Vasorelaxing Action of the Kynurenine Metabolite, Xanthurenic Acid: The Missing Link in Endotoxin-Induced Hypotension?. <i>Frontiers in Pharmacology</i> , 2017, 8, 214.	1.6	33
27	Personalised Healthcare: The DiMA Clinical Model. <i>Current Pharmaceutical Biotechnology</i> , 2017, 18, 242-252.	0.9	19
28	Degradation Rate of 5-Fluorouracil in Metastatic Colorectal Cancer: A New Predictive Outcome Biomarker?. <i>PLoS ONE</i> , 2016, 11, e0163105.	1.1	10
29	Pre-treatment evaluation of 5-fluorouracil degradation rate: association of poor and ultra-rapid metabolism with severe toxicity in a colorectal cancer patients cohort. <i>Oncotarget</i> , 2016, 7, 20612-20620.	0.8	21
30	Acute, transitional and long-term cluster headache treatment: pharmacokinetic issues. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 1011-1020.	1.5	5
31	Xanthurenic Acid Activates mGlu2/3 Metabotropic Glutamate Receptors and is a Potential Trait Marker for Schizophrenia. <i>Scientific Reports</i> , 2016, 5, 17799.	1.6	91
32	Precise medical decision making in geriatric anti-depressant therapy. <i>Expert Review of Precision Medicine and Drug Development</i> , 2016, 1, 387-396.	0.4	5
33	Systematic Review of Clozapine Cardiotoxicity. <i>Current Psychiatry Reports</i> , 2016, 18, 68.	2.1	68
34	Use of benzylglycinamide by a HIV-seropositive polysubstance user: The changing pattern of novel psychoactive substance use among youths. <i>Addictive Behaviors</i> , 2016, 60, 53-57.	1.7	1
35	The TYMS-TSER polymorphism is associated with toxicity of low-dose capecitabine in patients with advanced gastrointestinal cancer. <i>Anti-Cancer Drugs</i> , 2016, 27, 1044-1049.	0.7	11
36	Chronic migraine treatment: from OnabotulinumtoxinA onwards. <i>Expert Review of Neurotherapeutics</i> , 2016, 16, 1217-1227.	1.4	22

#	ARTICLE	IF	CITATIONS
37	Altered serum levels of kynurenine metabolites in patients affected by cluster headache. <i>Journal of Headache and Pain</i> , 2016, 17, 27.	2.5	41
38	Eletriptan in the management of acute migraine: an update on the evidence for efficacy, safety, and consistent response. <i>Therapeutic Advances in Neurological Disorders</i> , 2016, 9, 414-423.	1.5	28
39	Altered kynurenine pathway metabolites in serum of chronic migraine patients. <i>Journal of Headache and Pain</i> , 2016, 17, 47.	2.5	57
40	Hedonic sensitivity to natural rewards is affected by prenatal stress in a sex-dependent manner. <i>Addiction Biology</i> , 2016, 21, 1072-1085.	1.4	29
41	Choosing the safest acute therapy during chronic migraine prophylactic treatment: pharmacokinetic and pharmacodynamic considerations. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 399-406.	1.5	29
42	Impairment of left ventricular function early in treatment with clozapine. <i>International Clinical Psychopharmacology</i> , 2015, 30, 282-289.	0.9	20
43	Choosing the safest acute combination therapy during prophylactic treatment: pharmacokinetic and pharmacodynamic considerations. <i>Journal of Headache and Pain</i> , 2015, 16, A36.	2.5	1
44	Intestinal permeability in children with recurrent respiratory and gastrointestinal symptoms. <i>Journal of Paediatrics and Child Health</i> , 2015, 51, 1214-1220.	0.4	2
45	O066. Kynurenine pathway metabolites in cluster headache. <i>Journal of Headache and Pain</i> , 2015, 16, A87.	2.5	1
46	Integrated OMICS tools for personalised medicine. <i>Journal of Headache and Pain</i> , 2015, 16, A9.	2.5	0
47	A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience. <i>Journal of Headache and Pain</i> , 2015, 17, 1.	2.5	120
48	OnabotulinumtoxinA 155 U in medication overuse headache: a two years prospective study. <i>SpringerPlus</i> , 2015, 4, 826.	1.2	62
49	The therapeutic potential of novel anti-migraine acute therapies. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 141-144.	1.9	7
50	Fathoming the kynurenine pathway in migraine: why understanding the enzymatic cascades is still critically important. <i>Internal and Emergency Medicine</i> , 2015, 10, 413-421.	1.0	23
51	Pharmacogenetic insights into migraine treatment in children. <i>Pharmacogenomics</i> , 2014, 15, 1539-1550.	0.6	12
52	Low Prostate Concentration of Lycopene Is Associated with Development of Prostate Cancer in Patients with High-Grade Prostatic Intraepithelial Neoplasia. <i>International Journal of Molecular Sciences</i> , 2014, 15, 1433-1440.	1.8	39
53	Urinary concentration of 8-isoprostane as marker of severity of pediatric OSAS. <i>Sleep and Breathing</i> , 2014, 18, 723-729.	0.9	23
54	Cinnabarinic acid, an endogenous agonist of type-4 metabotropic glutamate receptor, suppresses experimental autoimmune encephalomyelitis in mice. <i>Neuropharmacology</i> , 2014, 81, 237-243.	2.0	48

#	ARTICLE	IF	CITATIONS
55	Treatment of menstrual migraine: utility of control of related mood disturbances. <i>Expert Review of Neurotherapeutics</i> , 2014, 14, 493-502.	1.4	7
56	Sumatriptan in clinical practice: effectiveness in migraine and the problem of psychiatric comorbidity. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 303-305.	0.9	13
57	Sodium channel antagonists for the treatment of migraine. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 1697-1706.	0.9	20
58	The omics in migraine. <i>Journal of Headache and Pain</i> , 2013, 14, 55.	2.5	30
59	Pharmacokinetic evaluation of almotriptan for the treatment of migraines. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013, 9, 637-644.	1.5	8
60	Intramuscular Aripiprazole in the Acute Management of Psychomotor Agitation. <i>Pharmacotherapy</i> , 2013, 33, 603-614.	1.2	26
61	Pharmacological enhancement of mGlu1 metabotropic glutamate receptors causes a prolonged symptomatic benefit in a mouse model of spinocerebellar ataxia type 1. <i>Molecular Brain</i> , 2013, 6, 48.	1.3	59
62	<scp>L</scp>-acetylcarnitine causes rapid antidepressant effects through the epigenetic induction of mGlu2 receptors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 4804-4809.	3.3	228
63	Early Life Stress Causes Refractoriness to Haloperidol-Induced Catalepsy. <i>Molecular Pharmacology</i> , 2013, 84, 244-251.	1.0	9
64	High-Performance Liquid Chromatography-Tandem Mass Spectrometry Method for Simultaneous Quantification of Carbamazepine, Oxcarbazepine, and Their Main Metabolites in Human Serum. <i>Therapeutic Drug Monitoring</i> , 2012, 34, 53-58.	1.0	10
65	CGRP receptor antagonists: an expanding drug class for acute migraine?. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 807-818.	1.9	63
66	Deciphering the task of N-acetyl aspartate in migraine. <i>Expert Review of Neurotherapeutics</i> , 2012, 12, 1057-1059.	1.4	6
67	Pharmacokinetic evaluation of zolmitriptan for the treatment of migraines. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2012, 8, 1043-1050.	1.5	14
68	Sumatriptan succinate: pharmacokinetics of different formulations in clinical practice. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 2369-2380.	0.9	27
69	Emerging treatment for chronic migraine and refractory chronic migraine. <i>Expert Opinion on Emerging Drugs</i> , 2012, 17, 393-406.	1.0	63
70	Treatment of Perimenstrual Migraine with Triptans: an Update. <i>Current Pain and Headache Reports</i> , 2012, 16, 445-451.	1.3	16
71	Re: Response to Anderson's Letter to the Editor. Comment on: Hemochromatosis and bipolar disorder, Serata et al. (2012) <i>Gen Hosp Psychiatry</i> 34(1)101.e1-101.e3. <i>General Hospital Psychiatry</i> , 2012, 34, 433-435.	1.2	0
72	An improved simple LC-MS/MS method for the measurement of serum aripiprazole and its major metabolite. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2012, 62, 135-139.	1.4	30

#	ARTICLE	IF	CITATIONS
73	Pharmacokinetic evaluation of frovatriptan. Expert Opinion on Drug Metabolism and Toxicology, 2011, 7, 1449-1458.	1.5	16
74	Ribavirin priming improves the virological response to antiviral treatment in transplanted patients with recurrent hepatitis C: a pilot study. Antiviral Therapy, 2011, 16, 879-885.	0.6	8
75	Lenalidomide for aggressive Bâ€cell lymphoma involving the central nervous system?. American Journal of Hematology, 2011, 86, 957-957.	2.0	16
76	Efficacy and tolerability of almotriptan in menstrual migraine: a comment. Expert Opinion on Pharmacotherapy, 2011, 12, 2279-2281.	0.9	8
77	Development of Asymptomatic Pancreatitis With Paradoxically High Serum Clozapine Levels in a Patient With Schizophrenia and the CYP1A2*1F/1F Genotype. Journal of Clinical Psychopharmacology, 2010, 30, 737-739.	0.7	13
78	Serum Levels of Risperidone and Its Metabolite, 9-Hydroxyrisperidone: Correlation Between Drug Concentration and Clinical Response. Therapeutic Drug Monitoring, 2009, 31, 475-481.	1.0	36
79	A Liquid Chromatography-Tandem Mass Spectrometry Method for the Determination of 5-Fluorouracil Degradation Rate by Intact Peripheral Blood Mononuclear Cells. Therapeutic Drug Monitoring, 2009, 31, 482-488.	1.0	31
80	A liquid chromatography/mass spectrometry method for the evaluation of intestinal permeability. Clinical Biochemistry, 2008, 41, 887-892.	0.8	52
81	HPLCâ€mass spectrometry method for quantitative detection of neuroendocrine tumor markers: Vanillylmandelic acid, homovanillic acid and 5-hydroxyindoleacetic acid. Clinica Chimica Acta, 2008, 398, 53-56.	0.5	65